Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update
14 nov. 2017 17h40 HE
|
Proteostasis Therapeutics, Inc.
Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and...
Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs
31 oct. 2017 16h05 HE
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects
31 juil. 2017 16h16 HE
|
Proteostasis Therapeutics, Inc
PTI-801 Moving to 14 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-428 Continues to Enroll 28 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-808 Investigational New Drug...
Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer
31 juil. 2017 16h15 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
29 juin 2017 07h00 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator
23 juin 2017 07h00 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
07 juin 2017 07h00 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
30 mars 2017 16h30 HE
|
Proteostasis Therapeutics, Inc
PTI-801 Receives FDA Fast Track Designation; Phase 1 Study Underway IND Submission for PTI-808 Planned for 2Q17 Phase 1 Study of PTI-428 Updated and Ongoing; Results Expected 2Q17 CAMBRIDGE, Mass.,...
Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results
10 nov. 2016 07h00 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference
26 oct. 2016 16h05 HE
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...